KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Payables (2017 - 2025)

Historic Payables for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $731.8 million.

  • Amneal Pharmaceuticals' Payables rose 905.1% to $731.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $731.8 million, marking a year-over-year increase of 905.1%. This contributed to the annual value of $735.4 million for FY2024, which is 2765.81% up from last year.
  • Per Amneal Pharmaceuticals' latest filing, its Payables stood at $731.8 million for Q3 2025, which was up 905.1% from $666.8 million recorded in Q2 2025.
  • Amneal Pharmaceuticals' Payables' 5-year high stood at $735.4 million during Q4 2024, with a 5-year trough of $467.4 million in Q1 2023.
  • For the 5-year period, Amneal Pharmaceuticals' Payables averaged around $597.1 million, with its median value being $589.4 million (2021).
  • As far as peak fluctuations go, Amneal Pharmaceuticals' Payables crashed by 1428.07% in 2021, and later soared by 2845.19% in 2024.
  • Amneal Pharmaceuticals' Payables (Quarter) stood at $525.3 million in 2021, then grew by 10.0% to $577.9 million in 2022, then decreased by 0.31% to $576.1 million in 2023, then rose by 27.66% to $735.4 million in 2024, then decreased by 0.49% to $731.8 million in 2025.
  • Its Payables was $731.8 million in Q3 2025, compared to $666.8 million in Q2 2025 and $628.6 million in Q1 2025.